oseen · source-linked reporting

The United States Food and Drug Administration orders manufacturers of GLP-1 medicines such as semaglutide

[https://www.bbc.com/news/articles/crwydyde0lp3o (BBC News)] [https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-orders-new-eye-risk-warnings-ozempic-zepbound-2026-11-09/ (Reuters)]

Published November 10, 2026· Updated November 11, 2026·1 min read

The United States Food and Drug Administration orders manufacturers of GLP-1 medicines such as semaglutide and tirzepatide, originally intended for the treatment of type 2 diabetes but also commonly used for weight loss, to add warnings that use of such drugs may increase the risk of developing non-arteritic anterior ischemic optic neuropathy, an optic nerve disorder that can cause permanent blindness. [https://www.bbc.com/news/articles/crwydyde0lp3o (BBC News)] [https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-orders-new-eye-risk-warnings-ozempic-zepbound-2026-11-09/ (Reuters)]

Event summary via Wikipedia Current Events (2026-11-10).